Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 596.91% and currently trading at $921.38. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Aura Biosciences Inc (AURA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market. This is thanks to Lilly's dominance in the billion-dollar weight loss drug market.
Little Support For Eli Lilly's High Valuation
An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due to expensive valuation. See more.
Morningstar3h
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in ...
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
EBGLYSS for eczema: What to know about the newly FDA-approved drug from Eli Lilly
The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Investor's Business Daily on MSN15h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
USA Today8d
New eczema drug from Eli Lilly receives FDA approval for children and adults
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
Ibj.com8h
Lilly seeks court ruling that could mean big money for new weight-loss drug
The Indianapolis-based drugmaker filed a suit in federal court this month, challenging the U.S. Food and Drug ...